ARN-75039 for Lassa Fever
What You Need to Know Before You Apply
What is the purpose of this trial?
This multicenter, randomized, open-label Phase 2 clinical trial evaluates the safety, tolerability, and virologic efficacy of ARN-75039, a novel oral antiviral, for treating Lassa fever in hospitalized adults in West Africa. The study is conducted within the INTEGRATE platform and compares two oral dose regimens of ARN-75039 (100 mg BID and 50 mg BID) with intravenous ribavirin, the locally mandated standard of care.
Approximately 135 participants with RT-PCR-confirmed Lassa virus infection will be enrolled and randomized 1:1:1 to receive ARN-75039 high dose, ARN-75039 low dose, or ribavirin for 10 days, followed by safety and efficacy follow-up through Day 28. The primary objectives are to assess safety and tolerability and to evaluate antiviral activity, as measured by the change in slope of Lassa virus RT-PCR cycle threshold (Ct) values from Day 1 to Day 10, in participants with low baseline viral load Ct values. Secondary objectives include additional virologic, pharmacokinetic, and clinical outcome assessments, including time to viral clearance, symptom resolution, organ failure, and mortality.
ARN-75039 is a small-molecule viral entry inhibitor targeting the Lassa virus glycoprotein complex and has demonstrated potent antiviral activity and favorable safety and pharmacokinetic profiles in preclinical models and Phase 1 clinical studies. This study aims to inform dose selection and support further clinical development of ARN-75039 as a potential treatment for Lassa fever.
Who Is on the Research Team?
Ken McCormack, PhD
Principal Investigator
Arisan Therapeutics, Inc.
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either ARN-75039 or ribavirin for 10 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
What Are the Treatments Tested in This Trial?
Interventions
- ARN-75039
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
ARN-75039 is an investigational oral antiviral agent administered as tablets. This high dose regimen includes a 150 mg initial dose and 100 second dose on day 1, followed by a 100 mg BID dose on day 2 and 50 mg BID days 3-10.
ARN-75039 is an investigational oral antiviral agent administered as tablets. This high dose regimen includes a 300 mg initial dose and 200 second dose on day 1, followed by a 200 mg BID dose on day 2 and 100 mg BID days 3-10.
Standard of Care "Irrua regimen"
Find a Clinic Near You
Who Is Running the Clinical Trial?
Arisan Therapeutics, Inc.
Lead Sponsor
Federal Medical Centre, Owo
Industry Sponsor
Battelle Memorial Institute
Collaborator
JPEO, Chemical, Biological, Radiological, and Nuclear, Medical
Collaborator
Alliance for International Medical Action
Collaborator
Irrua Specialist Teaching Hospital
Collaborator
Bernhard Nocht Institute for Tropical Medicine
Collaborator
ANRS, Emerging Infectious Diseases
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.